08:54 AM EDT, 07/17/2026 (MT Newswires) -- Arch Biopartners ( ACHFF ) has engaged a U.S.-based bioengineering laboratory to accelerate its chronic kidney disease program.

Arch is developing drug candidates that target interluekin-32 (IL-32), which is implicated in diabetic kidney disease.

The laboratory will perform studies to generate proprietary data and support Arch's patent portfolio covering its IL-32 drug candidates and related method-of-use claims.